Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines

Acta Psychiatrica Scandinavica

Volumn 138, Issue 3, 2018, Pages 196-222

  Verdolini, N ^a,b,c,d   Hidalgo Mazzei, D ^a,c,e   Murru, A ^a,c   Pacchiarotti, I ^a,c   Samalin, L ^a,f,g   Young, A H ^e   Vieta, E ^a,c   Carvalho, A F ^h,i  

^a UNIVERSITY OF BARCELONA   (Spain)

^b FIDMAG GERMANES HOSPITALÀRIES RESEARCH FOUNDATION   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSITY OF PERUGIA   (Italy)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^g Hopital Albert Chenevier   (France)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

bipolar disorder; guidelines; mixed features; mixed states; unipolar disorder

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CARIPRAZINE; CLOZAPINE; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; LURASIDONE; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE; TRANQUILIZER;

BIPOLAR DISORDER; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED PRACTICE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; META ANALYSIS; MIXED MANIA AND DEPRESSION; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; PROCEDURES; PSYCHOLOGY;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; LITHIUM; LURASIDONE HYDROCHLORIDE; OLANZAPINE; PALIPERIDONE PALMITATE; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; QUETIAPINE FUMARATE; THIAZOLES; VALPROIC ACID;

EID: 85047430192     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12896     Document Type: Review

References (204)

1. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016;387:1561–1572
2. Solé E, Garriga M, Valentí M, Vieta E. Mixed features in bipolar disorder. CNS Spectr 2017;22:134–140
3. Marneros A. Origin and development of concepts of bipolar mixed states. J Affect Disord 2001;67:229–240
4. Rosenblat JD, McIntyre RS. Treatment recommendations for DSM-5-defined mixed features. CNS Spectr 2017;22:147–154
5. Stahl SM. Mixed-up about how to diagnose and treat mixed features in major depressive episodes. CNS Spectr 2017;22:111–115
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th edn, Text Revision). Washington, DC: American Psychiatric Association, 2000
7. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th edn). Washington DC: American Psychiatric Association, 2013
8. Vieta E, Valentí M. Mixed states in DSM-5: implications for clinical care, education, and research. J Affect Disord 2013;148:28–36
9. McIntyre RS, Lee Y, Mansur RB. A pragmatic approach to the diagnosis and treatment of mixed features in adults with mood disorders. CNS Spectr 2016;21(S1):25–33
10. Kessing LV. The prevalence of mixed episodes during the course of illness in bipolar disorder. Acta Psychiatr Scand 2008;117:216–224
11. Verdolini N, Agius M, Ferranti L, Moretti P, Piselli M, Quartesan R. The state of the art of the DSM-5 “with mixed features” specifier. ScientificWorldJournal 2015;2015:757258
12. McIntyre RS, Soczynska JK, Cha DS et al. The prevalence and illness characteristics of DSM-5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord 2015;172:259–264
13. Malhi GS, Byrow Y, Outhred T, Fritz K. Exclusion of overlapping symptoms in DSM-5 mixed features specifier: heuristic diagnostic and treatment implications. CNS Spectr 2017;22:126–133
14. Takeshima M, Oka T. DSM-5-defined “mixed features” and Benazzi's mixed depression: which is practically useful to discriminate bipolar disorder from unipolar depression in patients with depression? Psychiatry Clin Neurosci 2015;69:109–116
15. Shim IH, Woo YS, Bahk W-M. Prevalence rates and clinical implications of bipolar disorder “with mixed features” as defined by DSM-5. J Affect Disord 2015;173:120–125
16. Tohen M, Gold AK, Sylvia LG et al. Bipolar mixed features – results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study. J Affect Disord 2017;217:183–189
17. Perugi G, Angst J, Azorin J-M et al. Mixed features in patients with a major depressive episode: the BRIDGE-II-MIX study. J Clin Psychiatry 2015;76:e351–e358
18. McElroy SL, Keck PE. Dysphoric mania, mixed states, and mania with mixed features specifier: are we mixing things up? CNS Spectr 2017;22:170–176
19. Verdolini N, Perugi G, Samalin L et al. Aggressiveness in depression: a neglected symptom possibly associated with bipolarity and mixed features. Acta Psychiatr Scand 2017;136:362–372
20. Targum SD, Suppes T, Pendergrass JC et al. Major depressive disorder with subthreshold hypomania (mixed features): clinical characteristics of patients entered in a multiregional, placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2016;68:9–14
21. Malhi GS. Diagnosis of bipolar disorder: who is in a mixed state? Lancet 2013;381:1599–1600
22. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry 2018;19:2–58
23. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85–116
24. Cuomo A, Nikolova VL, Yalin N, Arnone D, Fagiolini A, Young AH. Pharmacological treatment of mixed states. CNS Spectr 2017;22:186–195
25. Rosenblat JD, McIntyre RS. Treatment of mixed features in bipolar disorder. CNS Spectr 2017;22:141–146
26. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346–388
27. McIntyre RS, Suppes T, Tandon R, Ostacher M. Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder. J Clin Psychiatry 2017;78:703–713
28. Woo YS, Lee JG, Jeong J-H et al. Korean medication algorithm project for bipolar disorder: third revision. Neuropsychiatr Dis Treat 2015;11:493–506
29. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535
30. Graham R, Mancher M, Wolman D, Greenfield S, Steinberg E. Clinical practice guidelines we can trust. Washington, DC: National Academies Press, 2011:266
31. Nivoli AMA, Colom F, Murru A et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011;129:14–26
32. Nivoli AMA, Murru A, Goikolea JM et al. New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord 2012;140:125–141
33. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005;86:1–10
34. Brouwers MC, Kho ME, Browman GP et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010;182:E839–E842
35. My AGREE PLUS – AGREE Enterprise website. http://www.agreetrust.org/login/
36. Goodwin G, Haddad P, Ferrier I et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016;30:495–553
37. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–926
38. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593–596
39. Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97–170
40. Fountoulakis KN, Grunze H, Vieta E et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol 2017;20:180–195
41. Malhi GS, Bassett D, Boyce P et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015;49:1087–1206
42. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. https://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/developers/nhmrc_levels_grades_evidence_120423.pdf
43. Stahl SM, Morrissette DA, Faedda G et al. Guidelines for the recognition and management of mixed depression. CNS Spectr 2017;22:203–219
44. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11:81–109
45. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013;14:154–219
46. Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008;9:248–312
47. Fountoulakis KN, Yatham L, Grunze H et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithm. Int J Neuropsychopharmacol 2017;20:121–179
48. Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702–709
49. Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57:841–849
50. Baker RW, Tohen M, Fawcett J et al. Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol 2003;23:132–137
51. Baldessarini RJ, Hennen J, Wilson M et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol 2003;23:370–376
52. Tohen M, McIntyre RS, Kanba S, Fujikoshi S, Katagiri H. Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. J Affect Disord 2014;168:136–141
53. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11:673–686
54. Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LLL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry 2009;70:1540–1547
55. Tohen M, Chengappa KNR, Suppes T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62–69
56. Baker RW, Brown E, Akiskal HS et al. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry 2004;185:472–478
57. Suppes T, Eudicone J, McQuade R, Pikalov A, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008;107:145–154
58. Sachs G, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20:536–546
59. Young AH, Oren DA, Lowy A et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009;194:40–48
60. Zimbroff DL, Marcus RN, Manos G et al. Management of acute agitation in patients with bipolar disorder. J Clin Psychopharmacol 2007;27:171–176
61. El Mallakh RS, Vieta E, Rollin L, Marcus R, Carson WH, McQuade R. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). Eur Neuropsychopharmacol 2010;20:776–783
62. Kanba S, Kawasaki H, Ishigooka J, Sakamoto K, Kinoshita T, Kuroki T. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). World J Biol Psychiatry 2014;15:113–121
63. Vieta E, Bourin M, Sanchez R et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235–242
64. Vieta E, T'joen C, McQuade RD et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008;165:1316–1325
65. Vieta E, Nuamah IF, Lim P et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010;12:230–243
66. Berwaerts J, Xu H, Nuamah I, Lim P, Hough D. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2012;136:e51–e60
67. Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011;129:252–260
68. Keck PE, Versiani M, Warrington L, Loebel AD, Horne RL. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. J Clin Psychiatry 2009;70:844–851
69. Potkin SG, Keck PE, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25:301–310
70. Stahl S, Lombardo I, Loebel A, Mandel FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord 2010;122:39–45
71. Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 2011;11:101
72. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord 2013;145:62–69
73. McIntyre RS, Tohen M, Berk M, Zhao J, Weiller E. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord 2013;150:378–383
74. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 2009;11:815–826
75. Landbloom RL, Mackle M, Wu X et al. Asenapine: efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. J Affect Disord 2016;190:103–110
76. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010;122:27–38
77. Berk M, Tiller JWG, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry 2015;76:728–734
78. Szegedi A, Calabrese JR, Stet L et al. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32:46–55
79. Suppes T, Ketter TA, Gwizdowski IS et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord 2013;150:37–43
80. Zarate CA, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000;61:185–189
81. Catapano-Friedman L. Effectiveness of quetiapine in the management of psychotic depression in an adolescent boy with bipolar disorder, mixed, with psychosis. J Child Adolesc Psychopharmacol 2001;11:205–206
82. Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111–121
83. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania–a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573–585
84. Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin Ther 2011;33:1643–1658
85. Garriga M, Solé E, González-Pinto A et al. Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: results from a pilot, randomized controlled trial. Eur Neuropsychopharmacol 2017;27:959–969
86. Sachs GS, Greenberg WM, Starace A et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord 2015;174:296–302
87. Durgam S, Starace A, Li D et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2015;17:63–75
88. Calabrese JR, Keck PE Jr, Starace A et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder. J Clin Psychiatry 2015;00:284–292. Available from: http://www.psychiatrist.com/jcp/article/pages/2015/v76n03/v76n0306.aspx
89. Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S. Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II/III trials. Eur Neuropsychopharmacol 2015;25:1882–1891
90. Vieta E, Durgam S, Lu K, Laszlovszky I, Patel MEW. Efficacy of cariprazine in subgroups of bipolar patients with manic episodes, mixed episodes, and with or without psychotic symptoms. Eur Neuropsychopharmacol 2017;27:S936–S937
91. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005;187:229–234
92. Hirschfeld RMA, Keck PE, Kramer M et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057–1065
93. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005;15:75–84
94. Perlis RH, Baker RW, Zarate CA et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006;67:1747–1753
95. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146–1154
96. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270–280
97. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002;12:93–99
98. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218–1226
99. Weisler RH, Kalali AH, Ketter TA, SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65:478–484
100. Weisler RH, Keck PE, Swann AC et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005;66:323–330
101. Weisler RH, Hirschfeld R, Cutler AJ et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 2006;20:219–231
102. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108–111
103. Bowden CL, Swann AC, Calabrese JR et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006;67:1501–1510
104. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918–924
105. Swann AC, Bowden CL, Morris D et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54:37–42
106. Grunze H, Erfurth A, Amann B, Giupponi G, Kammerer C, Walden J. Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychopharmacol 1999;19:303–309
107. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006;8:15–27
108. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998;50:245–251
109. Chengappa KN, Rathore D, Levine J et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999;1:42–53
110. Vieta E, Torrent C, Garcia-Ribas G et al. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol 2002;22:431–435
111. Barzman DH, DelBello MP, Kowatch RA et al. Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 2005;15:931–937
112. Benedetti A, Lattanzi L, Pini S, Musetti L, Dell'Osso L, Cassano GB. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 2004;79:273–277
113. Mokhber N, Lane CJ, Azarpazhooh MR et al. Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran. Neuropsychiatr Dis Treat 2008;4:227–234
114. McElroy SL, Soutullo CA, Keck PE, Kmetz GF. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997;9:99–103
115. Perugi G, Toni C, Ruffolo G, Sartini S, Simonini E, Akiskal H. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsychiatry 1999;32:136–141
116. Altshuler LL, Keck PE, McElroy SL et al. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1999;1:61–65
117. Sokolski KN, Green C, Maris DE, DeMet EM. Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann Clin Psychiatry 1999;11:217–222
118. Vieta E, Martinez-Arán A, Nieto E et al. Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry 2000;15:433–437
119. Valentí M, Benabarre A, García-Amador M, Molina O, Bernardo M, Vieta E. Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. Eur Psychiatry 2008;23:53–56
120. Gruber NP, Dilsaver SC, Shoaib AM, Swann AC. ECT in mixed affective states: a case series. J ECT 2000;16:183–188
121. Medda P, Toni C, Mariani MG, De Simone L, Mauri M, Perugi G. Electroconvulsive therapy in 197 patients with a severe, drug-resistant bipolar mixed state. J Clin Psychiatry 2015;76:1168–1173
122. Strömgren LS. Electroconvulsive therapy in Aarhus, Denmark, in 1984: its application in nondepressive disorders. Convuls Ther 1988;4:306–313
123. Devanand DP, Polanco P, Cruz R et al. The efficacy of ECT in mixed affective states. J ECT 2000;16:32–37
124. Ciapparelli A, Dell'Osso L, Tundo A et al. Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. J Clin Psychiatry 2001;62:552–555
125. Medda P, Perugi G, Zanello S, Ciuffa M, Rizzato S, Cassano GB. Comparative response to electroconvulsive therapy in medication-resistant bipolar I patients with depression and mixed state. J ECT 2010;26:82–86
126. Patkar A, Gilmer W, Pae C et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One 2012;7:e34757
127. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder. J Clin Psychiatry 2009;70:1424–1431
128. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079–1088
129. Tohen M, McDonnell DP, Case M et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012;201:376–382
130. Loebel A, Cucchiaro J, Silva R et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171:160–168
131. Loebel A, Cucchiaro J, Silva R et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171:169–177
132. Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res 2016;78:86–93
133. McIntyre R, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry 2015;76:398–405
134. Suppes T, Silva R, Cucchiaro J et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2016;173:400–407
135. Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. CNS Spectr 2017;22:228–235
136. Tsai J, Thase ME, Mao Y, Ng-Mak D, Pikalov A, Loebel A. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study. CNS Spectr 2017;22:236–245
137. Sramek J, Loebel A, Murphy M, Mao Y, Pikalov A, Cutler NR. Lurasidone in post-menopausal females with major depressive disorder with mixed features: post-hoc analysis of a placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2017;78:12–17
138. Dilsaver SC, Swann SC, Chen Y-W et al. Treatment of bipolar depression with carbamazepine: results of an open study. Biol Psychiatry 1996;40:935–937
139. Perugi G, Medda P, Reis J, Rizzato S, Giorgi Mariani M, Mauri M. Clinical subtypes of severe bipolar mixed states. J Affect Disord 2013;151:1076–1082
140. Joas E, Karanti A, Song J, Goodwin GM, Lichtenstein P, Landén M. Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry 2017;210:197–202
141. Tohen M, Mintz J, Bowden CL. Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multi-state Outcome Analysis of Treatments (MOAT). Bipolar Disord 2016;18:282–287
142. Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281–1290
143. Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2013;(10):CD003196
144. Calabrese JR, Shelton MD, Rapport DJ et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162:2152–2161
145. Backlund L, Ehnvall A, Hetta J, Isacsson G, Ågren H. Identifying predictors for good lithium response – a retrospective analysis of 100 patients with bipolar disorder using a life-charting method. Eur Psychiatry 2009;24:171–177
146. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011;199:57–63
147. Weisler RH, Nolen WA, Neijber A, Hellqvist Å, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder. J Clin Psychiatry 2011;72:1452–1464
148. Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord 2013;15:100–109
149. Keller MB, Lavori PW, Coryell W, Endicott J, Mueller TI. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis 1993;181:238–245
150. Prien RF, Himmelhoch JM, Kupfer DJ. Treatment of mixed mania. J Affect Disord 1988;15:9–15
151. Bowden CL, Collins MA, McElroy SL et al. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology 2005;30:1932–1939
152. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481–489
153. Ketter TA, Kalali AH, Weisler RH, SPD417 Study Group. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65:668–673
154. Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247–256
155. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 2009;116:43–50
156. Tohen M, Chengappa KNR, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337–345
157. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109:251–263
158. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B, Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476–488
159. Vieta E, Suppes T, Ekholm B, Udd M, Gustafsson U. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord 2012;142:36–44
160. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130–137
161. Yatham LN, Fountoulakis KN, Rahman Z et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord 2013;147:365–372
162. Marcus R, Khan A, Rollin L et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011;13:133–144
163. Woo YS, Bahk W-M, Chung MY et al. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. Hum Psychopharmacol 2011;26:543–553
164. Carlson BX, Ketter TA, Sun W et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2012;14:41–53
165. Benabarre A, Vieta E, Colom F, Martínez A, Reinares M, Corbella B. Treatment of mixed mania with risperidone and mood stabilizers. Can J Psychiatry 2001;46:866–867
166. Woo YS, Bahk W-M, Jon D-I et al. Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea. Psychiatry Clin Neurosci 2010;64:28–37
167. Vanelle JM, Loo H, Galinowski A et al. Maintenance ECT in intractable manic-depressive disorders. Convuls Ther 1994;10:195–205
168. Medda P, Mauri M, Fratta S et al. Long-term naturalistic follow-up of patients with bipolar depression and mixed state treated with electroconvulsive therapy. J ECT 2013;29:179–188
169. Mosolov SNMS. Primenenie elektrosudorozhnoi terapii dlia obryva kontinual’- nogo techeniia terapevticheski rezistentnykh affektivnogo i shizoaffektivnogo psikhozov. Zh Nevropatol Psikhiatr Im S S Korsakova 1990;90:121–125
170. Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Depress Anxiety 2016;33:424–434
171. Pikalov A, Tsai J, Mao Y, Silva R, Cucchiaro J, Loebel A. Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment. Int J Bipolar Disord 2017;5:9
172. Calabrese JR, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017;27:865–876
173. Goldberg JF, Ng-Mak D, Siu C, Chuang C-C, Rajagopalan K, Loebel A. Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension. CNS Spectr 2017;22:220–227
174. Pacchiarotti I, Bond DJ, Baldessarini RJ et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249–1262
175. Solmi M, Murru A, Pacchiarotti I et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 2017;13:757–777
176. Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012;22:339–346
177. Vieta E, Berk M, Schulze TG et al. Bipolar disorders. Nat Rev Dis Primers 2018;4:18008
178. Murru A. Electroconvulsive therapy in bipolar mixed states: an overlooked option. J Clin Psychiatry 2015;76:e1149–e1150
179. Rosa AR, Cruz N, Franco C et al. Why do clinicians maintain antidepressants in some patients with acute mania? J Clin Psychiatry 2010;71:1000–1006
180. Montoya A, Pérez Sánchez Toledo J, Gilaberte I et al. Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM Study. Actas Esp Psiquiatr 2007;35:315–322
181. Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord 2016;18:174–182
182. Barbuti M, Pacchiarotti I, Vieta E et al. Antidepressant-induced hypomania/mania in patients with major depression: evidence from the BRIDGE-II-MIX study. J Affect Disord 2017;219:187–192
183. Valentí M, Pacchiarotti I, Rosa AR et al. Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar Disord 2011;13:145–154
184. Pacchiarotti I, Mazzarini L, Kotzalidis GD et al. Mania and depression. Mixed, not stirred. J Affect Disord 2011;133:105–113
185. Baldessarini RJ, Undurraga J, Vázquez GH et al. Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand 2012;125:293–302
186. Vieta E, Nolen WA, Grunze H, Licht RW, Goodwin G. A European perspective on the Canadian guidelines for bipolar disorder. Bipolar Disord 2005;7(Suppl 3):73–76
187. Mazzarini L, Kotzalidis GD, Piacentino D et al. Is recurrence in major depressive disorder related to bipolarity and mixed features? Results from the BRIDGE-II-Mix study. J Affect Disord 2018;229:164–170
188. Popovic D, Vieta E, Azorin J-M et al. Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study. Bipolar Disord 2015;17:795–803
189. Petri E, Bacci O, Barbuti M et al. Obesity in patients with major depression is related to bipolarity and mixed features: evidence from the BRIDGE-II-Mix study. Bipolar Disord 2017;19:458–464
190. Perugi G, Angst J, Azorin J-M et al. Relationships between mixed features and borderline personality disorder in 2811 patients with major depressive episode. Acta Psychiatr Scand 2016;133:133–143
191. Ratheesh A, Davey C, Hetrick S et al. A systematic review and meta-analysis of prospective transition from major depression to bipolar disorder. Acta Psychiatr Scand 2017;135:273–284
192. Kessing LV, Willer I, Andersen PK, Bukh JD. Rate and predictors of conversion from unipolar to bipolar disorder: a systematic review and meta-analysis. Bipolar Disord 2017;19:324–335
193. Morrissette DA. Do no harm: a paradigm shift in the unchecked use of antidepressants. CNS Spectr 2017;22:118–119
194. Stahl SM, Morrissette DA. Does a “whiff” of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic? Bipolar Disord 2017;19:595–596
195. Angst J, Cui L, Swendsen J et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010;167:1194–1201
196. Malhi GS, Kuiper S. Chronobiology of mood disorders. Acta Psychiatr Scand 2013;128:2–15
197. Malhi GS, Porter RJ. Are “buy-polar” forces and “try-polar” thinking expanding bipolarity? Aust N Z J Psychiatry 2014;48:697–700
198. Akiskal HS, Hantouche EG, Bourgeois ML et al. Gender, temperament, and the clinical picture in dysphoric mixed mania: findings from a French national study (EPIMAN). J Affect Disord 1998;50:175–186
199. Perugi G, Akiskal HS, Micheli C et al. Clinical subtypes of bipolar mixed states: validating a broader European definition in 143 cases. J Affect Disord 1997;43:169–180
200. Benazzi F. Age at onset of bipolar II depressive mixed state. Psychiatry Res 2001;103:229–235
201. Koukopoulos A, Sani G. DSM-5 criteria for depression with mixed features: a farewell to mixed depression. Acta Psychiatr Scand 2014;129:4–16
202. Kessing LV, Bauer M, Nolen WA, Severus E, Goodwin GM, Geddes J. Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord 2018.1–13. Available from: https://doi.org/doi.wiley.com/10.1111/bdi.12623
203. Swann AC. Mixed features: evolution of the concept, past and current definitions, and future prospects. CNS Spectr 2017;22:161–169
204. Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60:402–407